Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020

JAMA Netw Open. 2021 Jun 1;4(6):e2112044. doi: 10.1001/jamanetworkopen.2021.12044.

Authors

Inmaculada Hernandez¹, Deanna Rowe², Walid F Gellad³, Chester B Good²

Affiliations

¹ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla.
² University of Pittsburgh Medical Clinic Health Plan, Insurance Services Division, Pittsburgh, Pennsylvania.
³ Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Abstract

This cohort study used Medicaid data to examine trends in the use of and spending for hemophilia pharmaceuticals from 2005 to 2020.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Health Services Accessibility / statistics & numerical data*
Hemophilia A / drug therapy*
Humans
Insurance Coverage / statistics & numerical data
Managed Care Programs / standards*
Medicaid
Patient Satisfaction / statistics & numerical data*
Treatment Outcome
United States